Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
Japan’s Ministry of Health, Labor and Welfare (MHLW) on July 1 unveiled a reshuffled roster of senior officials with their appointments effective July 8. Councilor Naoki Miyamoto has been tapped as new director-general of the Pharmaceutical Safety Bureau. Miyamoto, currently…
To read the full story
Related Article
- MHLW Veteran Katsufumi Jo Joins BCG as Senior Advisor
November 5, 2025
- MHLW’s New Pharma Chief Pledges Safer, More Accessible Drug Environment
August 19, 2025
- Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
August 8, 2025
- MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies
August 6, 2025
- MHLW Official Urges Use of New Fund to Drive Reorganization of Generic Sector
August 4, 2025
- Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
- Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
- New MHLW Drug Review Chief Aims to Dispel “Barrier” Perception, Pledges Active Engagement with Industry
July 23, 2025
REGULATORY
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…